SORT BY Relevancy
When should patients start asking about involving an oncologist in their care, how can we manage quality of life issues while being treated for advanced, metastatic, and castration-resistant prostate cancer? We are discussing how to manage advanced and late stage prostate cancer with Dr Maha Hussain and panelists. The panel of Mike Scott, Tony Crispino, Richard Davis and Jan Manarite, will also be touching upon the results of important clinical trials from the upcoming GU oncology meeting.
Dr. Maha Hussain is a tenured Professor of Medicine and Urology at the University of Michigan. She is the Associate Director for Clinical Research at the University of Michigan Comprehensive Cancer Center (UMCC), the Co-Leader of its Prostate Cancer/GU Oncology Program and the Associate Chief for Clinical Research at the Division of Hematology/ Oncology. Dr. Hussain is an internationally renowned clinical researcher and an expert in genitourinary malignancies particularly prostate and bladder cancers.
On this show we have the Associate Director, Department of Urology, Roswell Park Cancer Institute Dr. James Mohler discussing the recent NCCN guidelines for prostate cancer treatment and the latest research available to us that can help diagnose high risk forms of prostate cancer and avoid unnecessary treatments for low risk forms. Tune in to get a better understanding of prostate cancer treatments and its management.
On the panel are Mike Scott, Tony Crispino and Paul Carpenter.
Dr. George Ibrahim is back to talk about sex over 40!
Part of Dr. Ibrahim's practice is devoted to sexual health and maintaining intimacy between couples. Men and Women both go through hormonal changes as we age and Dr. Ibrahim will tell us how he adresses it and helps couples (or singles) how to treat and remedy these issues to keep things interesting in the bedroom.
Dr. Ibrahim has 20+ years of experience as an urologist in a clinical hospital setting where he helped work with patients who had challenges that had typically reached a crisis level.
Now, at Asheville HealthSpan MD he gets the privilege of working with patients that are not in a life or death situation, but are looking at solving real problems with their sex lives and improve their overall health.
Some of the sexual health procedures that Dr. Ibrahim specializes in are:
Injection procedures that help develop more functional tissue in areas of sexual response
Erectile Dysfunction Procedures
Hormone Replacement for both Men and Women
This episode is R-rated!
Join me this week as I talk with Dr. George Ibrahim about Anti-Aging and Hormones for Men and Women!
Dr. Ibrahim has a hugely busy practice in Asheville, N.Carolina and is on the cutting edge of new technologies in Anti-Aging and Hormone Replacement Therapy.
A graduate of Davidson College, Duke University Medical School, and the Darla Moore School of Business at the University of South Carolina,
Dr. Ibrahim holds board certifications from the American Board of Urology and underwent a fellowship by the American Academy of Anti-Aging and Regenerative Medicine.
Prior to founding Asheville Healthspan MD, Dr. Ibrahim was an associate clinical professor of surgery at Duke University where he served as Chief of Urology at the Charles George Veterans Medical Center in charge of the Duke University Urology Residency Program.
His associations include: Member, North American Menopause Society; Fellow, American Academy of Anti-Aging Medicine; Diplomat, American Board of Urology; Member, North American Sexual Medicine Society; Member, Western North Carolina Medical Society. http://ashevillehealthspanmd.com/hormones/
MoonMaid Botanicals and Cynthia, the #menopause herbalist, present Women of a Certain Age and...... this is my opportunity to offer you information on a variety of topics that relate to the aging process, menopause and hormone imbalance. Lifestyle, nutrition, herbs, drugs, surgery, addiction, and breast health are just some of the topics we present in this program.This evenings topic is SEX.
My guest is Dr. Serena McKenzie , Medical Director of the Northwest Institute for Healthy Sexuality which addresses a wide variety of sexual concerns women and men in a multi-disciplinary clinic integrating both holistic and allopathic medicine. She works in fluid collaboration with a multitude of providers at Washington Urology and Urogynecology, PLLC. Her background is in primary care and she is certified in Integrative Medicine through the American Board of Integrative Medicine (ABIM). She is a sexual medicine expert, and a nationally certified Sex Counselor through the American Association of Sex Educators and Therapists (AASECT) as well as being a certified ISSWSH Fellow (IF) through International Society for Women’s Sexual Health (ISSWSH).
Dr. McKenzie is a member of the Washington Association of Naturopathic Physicians (WANP), International Society for Sexual Medicine (ISSM), American Association of Integrative Medicine (AAIM), Age Management Medical Group (AMMG), American Association of Sex Educators and Therapists (AASECT), International Society for the Study of Women’s Sexual Health (ISSWSH), and a founding member of the Naturopathic Academy of Primary Care Physicians (NAPCP).
Get excited for the next episode of the Pelvic Messenger, Stimulating Science with Dr. Kenneth Peters, on August 21, 2014 (1:30 PM EST).
Dr. Kenneth M. Peters is Professor and Chair of Urology at Oakland University William Beaumont School of Medicine in Rochester, Michigan. He is also Chair of Urology at Beaumont Health System in Royal Oak, Michigan, and Medical Director of the Women’s Urology Center in Royal Oak, a unique multidisciplinary center dedicated to women with chronic pelvic pain and voiding dysfunction. He graduated with honors from the University of Michigan in Ann Arbor and earned his medical degree from Case Western Reserve University School of Medicine in Cleveland, Ohio. Dr Peters subsequently completed his training in surgery and urology at William Beaumont Hospital, where he also completed a fellowship in female urology and urodynamics.
Widely recognized as a leader in research, Dr. Peters is internationally known for his work on interstitial cystitis, neuromodulation for voiding dysfunction, nerve rerouting surgery to restore voiding in spina bifida patients, and adult human stem cell injection for stress urinary incontinence.
Dr. Peters is an active and well-respected clinician, educator and researcher. He specializes in the treatment of voiding dysfunction and female urology. He has written numerous peer-reviewed journal articles and book chapters on incontinence, interstitial cystitis and neuromodulation. He has twice won the Society for Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) clinical research award.
James Smolev, MD, chief of Urology at MedStar Good Samaritan Hospital will visit with Anna's Journey to discuss the importance of early detection and the possibility of a 90+% chance of recovery from Prostate Cancer.
As September is Prostate Cancer Awareness... and following this past weekend's big walk for Prostate Cancer, Anna's Journey is doing more to help raise that awareness... with the help of Dr. Smolev, listeners will have the opportunity to share this info with all those in their family, with friends and anyone else who may need to hear it.
Myrbetriq®'s Advertising Partnership with RunPee App
Pharmaguy interviews Walt Johnston, Vice President of US Marketing and New Product Planning, and Emily Sitrin Mason, Consumer Marketing Director - Urology Franchise, at Astellas (see Bios). We discuss a new partnership with Astellas Pharma US and the RunPee mobile app as part of the company's marketing campaign for Myrbetriq® (mirabegron) featuring an animated bladder character.
The RunPee app is a movie-viewing app that tells you the best time to "run and pee" without missing the best scenes. While the ultimate goal is to encourage individuals to speak with a health care professional about overactive bladder (OAB), Astellas is encouraging those who experience symptoms of OAB to enjoy the movies this summer and download the app to determine the best time to use the restroom during movies if needed.
Questions/Topics of Discussion
Give us a little background about this partnership. Why did Astellas decide to partner with RunPee?
Describe how the app works
Are branded Myrbetriq® ads served up within the app? Describe how that is done.
What is the target audience for Myrbetriq® and how does the app help you reach this audience?
What are are the KPIs for this campaign? Has it been successful so far? What data can you share with us?
What have you learned from this partnership?
Renal cell carcinoma is a very rare cancer that represents the most common form of Kidney Cancer; and it is occuring more frequently in young adults. With no actual preventon or early detection methods, if not somehow caught early, prognosis for remission are very low. Join us as we welcome AYA/RCC survivor Lauren Hassell and Dr. Carl Bischoff, board certified urologic oncologist and RCC specialist to shed light on this underdiscussed orphan disease. Survivor spotlght on Steven Robinson.
Dr. Ian Thompson is Professor, Glenda and Gary Woods Distinguished Chair in GU Oncology at The University of Texas Health Science Center, San Antonio. Dr. Ian Thompson received his undergraduate degree from West Point and his M.D. degree from Tulane University. After a Residency in Urology in San Antonio, he completed a fellowship in Urologic Oncology at Memorial Sloan Kettering Cancer Center. Dr. Thompson has published over 400 scientific papers, several dozen book chapters, and has edited five textbooks in medicine and surgery. He currently serves as Vice-Chair of the Early Detection Research Network of the National Cancer Institute and is Chair of the Genitourinary Committee of the Southwest Oncology Group, the largest clinical trials organization supported by the National Cancer Institute. Dr. Thompson is the Principal Investigator of the San Antonio Center for Biomarkers Of Risk of Prostate Cancer. This cohort study, with up to 8 years of followup, currently follows over 3,600 men for development of prostate cancer and has been the source of many recent important developments in the early detection of prostate cancer.
Our prostate cancer panels are conducted in association with Prostate Cancer International and Prostate Cancer Foundation.
RSVP here (or) mail firstname.lastname@example.org
“It's not the men in your life that matters; it's the life in your men.” ~ Mae West
Dr. Marc Richman is the co-founder of Obsidian Men’s Health, a premier men’s sexual-health institute where they focus on enhancing the sex lives — and thereby the overall health and well-being — of men and their partners. They offer a private-concierge experience, personally tailored to each individual’s desired level of sexual performance. They diagnose and treat with a single purpose in mind: to promote an extraordinary sex life for each of their clients.
Dr. Marc is a urologist certified by the American Board of Urology, and a member of the American Urologic Association. He earned his medical degree, summa cum laude, at the State University of New York at Buffalo, where he was elected into Alpha Omega Alpha.
Dr. Marc has won an unprecedented four Pfizer Awards at the University of North Carolina at Chapel Hill, at which he completed his general-surgery internship and residency in urologic surgery. There, he studied under the renowned Dr. Culley C. Carson, an expert in men’s sexual health.
With more than 10 years’ experience diagnosing and treating men’s health, Dr. Marc has treated clients throughout the world, including a number of global leaders and dignitaries.
You can learn more about Dr. Richman’s work in men’s sexual health via his website, Facebook, Twitter, and Google+.
We were honored to feature Dr. Laurence Klotz, an acknowledged authority on active surveillance for the management of low-risk prostate cancer. Dr. Klotz is Professor in the Department of Surgery, University of Toronto Division of Urology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Dr. Klotz and panelists discussed evidence supporting value of active surveillance as a management strategy for men who are diagnosed with low- or very low-risk forms of prostate cancer. Dr. Klotz spoke particularly about factors that are key to the high-quality implementation of active surveillance, including accumulating evidence that true Gleason 6 disease is not associated with any significant risk for metastasis, importance of early identification of patients who do, in fact, have real risk for disease progression over time, are therefore not good candidates for active surveillance, and managing these patients, evolving strategies to minimize need for overly frequent (i.e., annual) biopsies, including potential role of multiparametric MRIs and new biomarkers, as also whether active surveillance is appropriate for a subset of men with Gleason 3 + 4 = 7 disease who have a very small volume Gleason pattern 4 disease.
On the panel were Mike Scott, Thomas N. Krik, Tony Crispino and Walter Green Jr.